A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells

Therapeutic vaccines that augment T cell responses to tumor antigens have been limited by poor potency in clinical trials. In contrast, the transfer of T cells modified with foreign transgenes frequently induces potent endogenous T cell responses to epitopes in the transgene product, and these respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Veatch, Joshua R., Singhi, Naina, Srivastava, Shivani, Szeto, Julia L., Jesernig, Brenda, Stull, Sylvia M., Fitzgibbon, Matthew, Sarvothama, Megha, Yechan-Gunja, Sushma, James, Scott E., Riddell, Stanley R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363286/
https://www.ncbi.nlm.nih.gov/pubmed/34396986
http://dx.doi.org/10.1172/JCI144195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363286/
https://www.ncbi.nlm.nih.gov/pubmed/34396986
http://dx.doi.org/10.1172/JCI144195

Ejemplares similares